Cartilage Regeneration Injections: How They Work & What to Expect

Cartilage regeneration injections deliver biologically active substances directly into a damaged joint with the goal of slowing cartilage breakdown, reducing pain, and in some cases encouraging new cartilage growth. The category includes several distinct therapies, from hyaluronic acid and platelet-rich plasma to stem cell concentrates and experimental growth factors, and each works through different mechanisms with different track records. The honest picture is that most of these injections reliably improve pain and function, but measurable cartilage regrowth on imaging remains modest and inconsistent across studies.

Hyaluronic Acid Injections

Hyaluronic acid (HA) is a naturally occurring molecule in joint fluid that gives it its thick, slippery quality. In a healthy knee, HA keeps cartilage surfaces lubricated and absorbs shock. In osteoarthritis, the concentration and molecular weight of HA in joint fluid drop, which contributes to stiffness and friction. Injecting supplemental HA, sometimes called viscosupplementation, aims to restore some of that lost lubrication.

But the injections do more than just add slipperiness. A systematic review found that chondroprotection was the most frequently reported mechanism of HA injections, meaning HA appears to shield cartilage cells from further damage. HA also stimulates the production of proteoglycans and glycosaminoglycans, the structural molecules that give cartilage its firmness, and it tamps down inflammation in the joint lining. High molecular weight HA products performed better than lower molecular weight versions across these effects.¹

A more recent targeted review confirmed this picture and added detail: HA injections increased levels of anabolic biomarkers associated with healthy cartilage (like type II collagen) while reducing catabolic enzymes that break cartilage down. Inflammatory mediators in the joint fluid also dropped after treatment, and the mechanical properties of the fluid improved, with higher viscosity and lower friction. Patients experienced meaningful pain reduction.²

HA injections are among the most established regenerative-adjacent treatments, widely available and covered by some insurance plans. The catch is that “regeneration” is a stretch for most HA products. They slow damage and manage symptoms effectively, but they are better thought of as maintenance therapy than as a tool to rebuild lost cartilage.

Platelet-Rich Plasma (PRP)

PRP is made from your own blood. A small draw is spun in a centrifuge to concentrate the platelets, which are cell fragments packed with growth factors and signaling proteins. When injected into a joint, these concentrated platelets release a cocktail of molecules that influence cartilage metabolism, inflammation, and tissue repair.

The biological rationale is well documented. PRP stimulates mesenchymal stem cell migration and differentiation into cartilage-producing cells, and it modulates the inflammatory pathways that drive cartilage breakdown.³ Laboratory and animal studies suggest that PRP affects several molecular signaling pathways involved in cartilage repair, inflammation control, and the maintenance of the cartilage matrix.⁴

Clinically, PRP reliably reduces pain. In one study of patients with moderate knee osteoarthritis, pain scores dropped dramatically over 12 months, with the biggest improvements in the first three months. But MRI measurements of cartilage thickness showed only a statistically insignificant change.⁵ A randomized trial comparing PRP to saline placebo found that PRP groups had significantly better pain scores, walking distance, and range of motion at six months, along with thicker medial tibial and patellar cartilage. PRP did not, however, reduce osteophytes (bone spurs) or subchondral cysts compared to placebo.⁶

A 3D-MRI study added geographic nuance. After PRP injection, the areas where cartilage thickened most were not always the areas most damaged by osteoarthritis. In the regions typically hit hardest by medial knee osteoarthritis, fewer than one in five knees showed increased cartilage thickness.⁷ That is a sobering finding: PRP may encourage cartilage growth, but not reliably where you need it most.

The Gap Between Feeling Better and Growing Cartilage

This disconnect between symptom relief and structural repair runs through almost every regenerative injection therapy. Patients often feel significantly better, with less pain, more mobility, and better daily function. But when researchers look at MRI scans, the cartilage itself may look about the same. One review of mesenchymal stem cell injections for knee osteoarthritis characterized the evidence as showing symptomatic improvement with only minimal structural improvement on MRI.⁸

This does not mean the pain relief is illusory. The injections likely work on the inflammatory environment inside the joint, the quality of the joint fluid, and the sensitivity of pain-sensing nerve endings, all of which can improve how a joint feels without necessarily adding measurable cartilage volume. For many patients, that relief is the whole point. But if you are being told an injection will “regrow” your cartilage, the imaging evidence suggests you should temper that expectation.

Stem Cell and Bone Marrow Injections

Bone marrow aspirate concentrate (BMAC) is drawn from the pelvic bone using a needle, then concentrated and injected into the joint. The concentrate contains mesenchymal stem cells along with growth factors and anti-inflammatory cytokines.⁹ The idea is that these stem cells can differentiate into cartilage-producing cells once inside the joint, while the growth factors create a favorable repair environment. The bone marrow clot itself can even act as a three-dimensional scaffold, providing a structure for new cartilage cells to organize within.¹⁰

BMAC is one of the pricier options, and there is more variation in how clinics prepare and administer it compared to PRP. The aspiration procedure itself is more involved than a simple blood draw, requiring numbing of the hip area and a larger needle to access the bone marrow.

Adipose-Derived Stem Cell Injections

Fat tissue is another rich source of mesenchymal stem cells. In this approach, a small amount of fat is harvested (usually via a mini-liposuction from the abdomen or thigh), processed to isolate the stem cells, and injected into the joint. A meta-analysis of randomized controlled trials found that adipose-derived stem cell injections showed significant improvement in cartilage integrity on MRI compared to controls after six and 12 months, including measurable increases in cartilage volume.¹¹

Dose appears to matter. In a two-year follow-up study, patients who received high-dose adipose-derived stem cell injections maintained improvements in knee function and pain for the full two years, while those in lower-dose groups saw their gains start to fade after the first year. MRI findings followed the same pattern.¹² This suggests that getting enough cells into the joint is critical, and that underdosing may explain some of the inconsistency in results across different clinics.

How Corticosteroid Injections Compare

Many patients receiving regenerative injections have already tried corticosteroid (cortisone) shots, which remain the most common joint injection in standard medical practice. Steroids are potent anti-inflammatories and can provide fast pain relief, often within days. But they work by suppressing the immune response rather than promoting tissue repair, and the long-term picture is less favorable.

Research has raised concerns that repeated corticosteroid injections may actually harm cartilage over time. Steroids have been reported to reduce collagen production, suppress cell growth, and introduce oxidative stress into joint tissues, potentially accelerating cartilage degradation.¹³ In that same randomized study, PRP outperformed corticosteroids at the one-year mark, likely because the steroid group’s cartilage environment continued to deteriorate while PRP’s biological effects shifted the joint toward repair rather than suppression.

This does not mean steroids have no role. For acute flare-ups, they remain effective short-term tools. But if the goal is long-term joint preservation, the regenerative therapies have a philosophical and biological advantage: they aim to change the trajectory of the disease rather than mask it.

Recombinant Growth Factors

Sprifermin, a lab-made version of fibroblast growth factor 18, represents a different approach: instead of introducing cells or cell products, it delivers a single defined protein that directly stimulates cartilage cells to produce new tissue. In a randomized, placebo-controlled trial, sprifermin produced dose-dependent reductions in cartilage loss and joint space narrowing in the knee.¹⁴

A post-hoc analysis of a phase II trial went further: the highest dose of sprifermin not only reduced cartilage thinning to levels comparable to healthy joints but also doubled the amount of cartilage thickening compared to what occurs naturally in people without osteoarthritis.¹⁵ Lab work on human cartilage tissue helped explain why: sprifermin triggers a two-phase remodeling process in which collagen production initially dips before ramping up significantly, suggesting the drug first reorganizes the tissue before building new matrix.¹⁶

Sprifermin is not yet commercially available and is still working through clinical trials, but the structural results so far are some of the most convincing in the regenerative injection space. Unlike many biologics, where pain improvement outpaces imaging changes, sprifermin has shown actual measurable cartilage gain.

The Placebo Problem

One of the trickiest aspects of evaluating any injection therapy for joints is the placebo effect, and it is larger than most patients (and some clinicians) realize. A meta-analysis found that the functional improvements from placebo injections in knee osteoarthritis were significant and long-lasting, persisting even beyond the duration of pain relief.¹⁷ Another systematic review concluded that the effect size of placebo in osteoarthritis trials is substantial and often larger than the additional benefit of the active treatment itself.¹⁸

The placebo effect in injection trials is especially strong because the act of getting an injection is itself a powerful medical ritual. Needles, clinical settings, a procedure performed by a specialist: all of it primes the brain to expect improvement. Research has found that the strength of the placebo response varies depending on what active treatment it is being compared against, suggesting that how patients perceive the therapy affects how much benefit they get from any injection.¹⁹

This does not mean regenerative injections are placebos. PRP, for instance, outperforms saline in blinded trials on measurable outcomes like cartilage thickness. But it does mean that some portion of the dramatic improvement patients report after any injection, regenerative or not, comes from the injection experience itself rather than the substance injected. For you as a patient, the practical takeaway is that any single anecdote, including your own, is not reliable evidence of whether the biological product itself made the difference.

Why Your PRP Is Not the Same as Someone Else’s

PRP preparation is one of the least standardized things in medicine. The centrifugal force used, the duration of spinning, the number of spins, and whether white blood cells are included or excluded all change the final product. A study examining different preparation protocols found that varying the centrifugal force and time produced significant changes in both the cellular composition and the growth factor concentrations of the resulting PRP.²⁰

This means two patients getting “PRP injections” at two different clinics could receive substantially different products with different concentrations of the active ingredients that matter. It also makes comparing clinical trials difficult, since one study’s PRP is not necessarily equivalent to another’s. When evaluating a clinic’s claims about PRP outcomes, asking about their specific preparation protocol is reasonable but unlikely to yield a useful answer unless you have a comparison benchmark.

BMAC has the same problem, compounded by variation in the source material: the number of stem cells in bone marrow differs significantly from person to person and declines with age. Survey data from practitioners shows large variation in treatment costs for both PRP and bone marrow concentrate, with BMAC being the most expensive and having the widest cost range across clinics. Private practice settings tend to charge more than academic medical centers.²¹

Safety and What to Expect After the Procedure

The injection itself is usually quick, typically done under ultrasound guidance to ensure the needle reaches the joint space. Ultrasound guidance is standard for most joint injections today, though accuracy can vary by joint. The procedure generally takes under 30 minutes including preparation and imaging.

Side effects from regenerative injections tend to be mild. The most common reactions are temporary pain, swelling, and stiffness at the injection site, usually lasting a few days. Some patients experience a “flare” in the first 24 to 48 hours, where the joint feels worse before improving. This is thought to reflect the initial inflammatory response triggered by the injected material, which is part of the therapeutic process.

Infection is the most serious risk, though it is rare when standard sterile technique is followed. Septic arthritis, a joint infection, is always a possibility with any needle entering a joint space, and clinicians need to maintain strict aseptic precautions.²² For newer investigational agents, many studies have been limited by small sample sizes, short follow-up periods, and in some cases the presence of serious side effects that need further investigation.²³

After the injection, most clinics recommend relative rest for 24 to 48 hours, avoiding heavy exercise or prolonged standing. Some protocols restrict anti-inflammatory medications for a period after PRP or stem cell injections, since the inflammatory cascade they trigger is considered part of the healing process. Full return to normal activity usually happens within a week, and the therapeutic effects often take several weeks to become noticeable.

Who Tends to Get the Best Results

Not everyone responds equally to regenerative injections, and certain patient characteristics predict better outcomes. Younger age, lower body weight, smaller cartilage defects, and earlier stages of osteoarthritis have all been associated with more favorable results, though the data is not yet strong enough to draw firm cutoff values for who should and should not receive treatment.²⁴

This pattern makes biological sense. A joint that still has a reasonable amount of cartilage remaining gives the injected material something to work with: cells to protect, a matrix to reinforce, an inflammatory environment that can be redirected. In advanced osteoarthritis, where cartilage is nearly gone and the bone surfaces are grinding together, there may not be enough biological infrastructure left for regenerative signals to act on. Clinics that offer regenerative injections for bone-on-bone joints are, at best, providing symptom management and inflammation control rather than meaningful regeneration.

Mechanical factors also play a role. If your knee is severely malaligned, with abnormal loading patterns that concentrate force on one spot, an injection alone is unlikely to overcome the ongoing mechanical damage. In those situations, addressing alignment through bracing, physical therapy, or surgical correction may be a necessary complement to any biologic therapy.

Exercise and Rehabilitation as Multipliers

There is evidence that combining injections with structured exercise produces better outcomes than either approach alone. A study comparing hyaluronic acid injections, exercise-based rehabilitation, and the combination of both found that the combined approach showed significant early improvement in pain compared to exercise alone, while the group receiving only HA injections saw their gains erode between one and six months, worsening significantly on pain, stiffness, and function measures.²⁵

The logic is straightforward: injections change the biochemical environment inside the joint, but controlled mechanical loading stimulates cartilage metabolism and strengthens the muscles that stabilize the joint. One without the other leaves part of the problem unaddressed. If you are investing in regenerative injections, pairing them with a rehab program designed to progressively load the joint is one of the clearest ways to protect your investment.

Emerging Approaches Still in the Lab

Several newer strategies are working their way toward clinical use. Exosome therapy uses tiny vesicles shed by stem cells rather than the stem cells themselves. These vesicles carry signaling molecules that promote cartilage repair and reduce inflammation. A systematic review and meta-analysis of animal studies found that stem cell-derived exosomes promoted cartilage repair by boosting the production of structural cartilage proteins and suppressing the enzymes that degrade them.²⁶ Additional lab work has shown that bone marrow-derived exosomes can prevent cartilage cells from undergoing programmed cell death and protect against inflammatory damage.²⁷

Injectable hydrogels represent another frontier. These are gel-like materials that can be injected as a liquid and then solidify inside the joint, mimicking the structure of natural cartilage. They can be loaded with cells, growth factors, or drugs and tailored to fill irregularly shaped defects. Hydrogels have been engineered in the lab with mechanical properties similar to native cartilage.²⁸ Their advantage over simple fluid injections is that they can stay in place and provide a scaffold for tissue growth, adapting to the irregular surfaces of damaged cartilage.²⁹

Gene therapy injections are the most futuristic option. Early-phase clinical trials have used viral vectors to deliver genes encoding growth factors or anti-inflammatory proteins directly into joint tissues. The idea is to turn the patient’s own cells into sustained drug factories, producing repair signals continuously rather than relying on a one-time injection of proteins that degrade within days. Most clinical work so far has focused on safety rather than efficacy, using adenovirus vectors to deliver genes for growth factors or anti-inflammatory molecules in patients with osteoarthritis.³⁰ These therapies remain years from routine clinical availability, but they represent a conceptual leap: instead of adding a product to the joint, you reprogram the joint’s own biology.